|
CDCA3 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.111200E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.862000E-01 |
| Normal-vs-Stage2 |
1.754400E-01 |
| Normal-vs-Stage3 |
3.264600E-01 |
| Normal-vs-Stage4 |
7.012600E-01 |
| Stage1-vs-Stage2 |
7.882000E-02 |
| Stage1-vs-Stage3 |
4.225400E-01 |
| Stage1-vs-Stage4 |
5.739800E-01 |
| Stage2-vs-Stage3 |
4.152200E-01 |
| Stage2-vs-Stage4 |
6.938300E-02 |
| Stage3-vs-Stage4 |
2.508400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.233200E-01 |
| Normal-vs-AfricanAmerican |
1.358040E-01 |
| Normal-vs-Asian |
6.826200E-01 |
| Caucasian-vs-AfricanAmerican |
4.949900E-02 |
| Caucasian-vs-Asian |
6.991800E-01 |
| AfricanAmerican-vs-Asian |
7.144000E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.234600E-01 |
| Normal-vs-Female |
3.787400E-01 |
| Male-vs-Female |
4.473200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.386000E-01 |
| Normal-vs-Age(41-60Yrs) |
1.603640E-01 |
| Normal-vs-Age(61-80Yrs) |
4.602400E-01 |
| Normal-vs-Age(81-100Yrs) |
3.805800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.701000E-03 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.278600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.464600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.052640E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.284240E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.048400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.115440E-01 |
| Classical-VS-Follicular |
5.457100E-03 |
| Classical-VS-Other |
2.073400E-01 |
| Classical-VS-Normal |
5.901200E-01 |
| Tall-VS-Follicular |
6.356000E-01 |
| Tall-VS-Other |
9.511600E-01 |
| Tall-VS-Normal |
2.385600E-01 |
| Follicular-VS-Other |
8.360600E-01 |
| Follicular-VS-Normal |
1.428420E-01 |
| Other-VS-Normal |
2.460600E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.879600E-01 |
| Normal-vs-N1 |
4.916000E-01 |
| N0-vs-N1 |
7.017600E-01 |
|
|
